I just rewatched the webinar and there were definitely some...

I just rewatched the webinar and there were definitely some valuable insights shared. One particularly notable case involved a 60-year-old woman who had undergone 4-5 lines of therapy before receiving Azer-cel, which resulted in a complete response. One of the therapies that failed was Yescarta, a treatment that generated $380millionUSD in Q1 of 2024 alone (1.5bn in 2023). This highlights the remarkable impact Azer-cel can have, even in cases where other significant therapies have not succeeded.





https://www.gilead.com/news-and-press/press-room/press-releases/2024/4/gilead-sciences-announces-first-quarter-2024-financial-results#:~:text=Yescarta®%20(axicabtagene%20ciloleucel)%20sales,”)%20outside%20the%20United%20States.